WHO invites national public health authorities, technical partners, civil society organizations, affected communities, youth- and key population-led groups, health-care providers, academia, research institutions, professional associations, private sector actors, donors, development agencies, and intergovernmental organizations to participate in the public consultation on the Integrated Global Action Plan (i-GAP) for Drug Resistance in HIV, Hepatitis B and C, and Sexually Transmitted Infections 2025–2030.
The i-GAP 2025-2030 will set out a unified global strategy to address increasing concerns about drug resistance across these major communicable diseases. Rooted in the WHO Global Health Sector Strategies for HIV, viral hepatitis and STIs (2022–2030), and aligned with the Global Action Plan on Antimicrobial Resistance and the Sustainable Development Goals, the i-GAP 2025-2030 will contribute to the broader international response to antimicrobial resistance while promoting responsible stewardship and equitable access to effective tools for prevention, diagnosis, and treatment.
This public consultation provides an important opportunity to strengthen the clarity, coherence, and implementation value of the i-GAP through focused input. WHO welcomes constructive technical and strategic feedback prior to its finalization.
How to participate
Participants are invited to review the consultation draft and submit written feedback by 28 August 2025 via the online feedback form.
Feedback is welcome in any language, and submissions may be made individually or on behalf of networks, consortia, or institutions. WHO encourages consolidated inputs from global and regional health partners, civil society coalitions, professional associations, laboratory networks, and WHO collaborating centres to reduce duplication and highlight shared priorities.
Guiding questions
To help focus feedback on the most critical elements of the i-GAP for drug resistance in HIV, hepatitis B and C, and sexually transmitted infections (2025–2030), we encourage respondents to consider the following questions when reviewing the consultation draft:
- Do the guiding principles of the i-GAP appropriately support its vision, goal, and implementation across settings and stakeholders? If not, are there principles that should be clarified, strengthened, or more explicitly reflected in the action framework?
- Are the proposed strategic objectives and areas of work sufficiently clear and actionable for the different actors? If not, please suggest specific areas where greater clarity is needed.
- Does the i-GAP strike an appropriate balance between integrated and disease-specific approaches to addressing drug resistance in HIV, hepatitis B and C, and STIs? If not, what suggestions do you have to enhance integration while maintaining disease-specific relevance?
- Are there any critical components, enablers, or actions missing from the proposed framework that would strengthen its strategic value or impact? Please specify any gaps or redundancies you have identified.